{
    "clinical_study": {
        "@rank": "65609", 
        "arm_group": [
            {
                "arm_group_label": "Euflexxa, 2 ml unit dose", 
                "arm_group_type": "Active Comparator", 
                "description": "Euflexxa\u00ae (hyaluronic acid of bacterial origin; Ferring Pharmaceuticals Inc., Parsippany, NJ) supplied as a 2 ml unit dose prefilled in a 2.25 ml glass syringe. Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2. Subjects will be observed an additional 24 weeks."
            }, 
            {
                "arm_group_label": "Supartz, 2.5 ml unit dose", 
                "arm_group_type": "Active Comparator", 
                "description": "SUPARTZ\u00ae (hyaluronic acid of avian origin; Seikagaku Corporation, Tokyo, Japan) supplied as a 2.5 mL unit dose prefilled in a 5 mL plastic syringe. Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2. Subjects will be observed an additional 24 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate non-inferiority of three weekly intra-articular\n      injections of SUPARTZ to three weekly intra-articular injections of Euflexxa for the relief\n      of knee OA."
        }, 
        "brief_title": "Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ\u00ae vs 3 Weekly Injections of Euflexxa\u00ae for Knee OA", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoarthritis", 
        "condition_browse": {
            "mesh_term": "Osteoarthritis"
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to demonstrate non-inferiority of three weekly intra-articular\n      injections of SUPARTZ to three weekly intra-articular injections of Euflexxa for the relief\n      of knee joint pain in subjects with osteoarthritis (OA) of the knee as measured by the VAS\n      (0-100 mm) Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain\n      subscale score Change from Baseline (CFB) over Weeks 3, 6, 12.\n\n      Safety will be accessed by recording adverse events, concomitant medications, physical\n      examinations, and vital signs."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical evidence of symptomatic osteoarthritis of the study knee as classified\n             according to Altman criteria.\n\n          -  Symptoms in study knee for at least one year prior to the screening visit\n\n          -  Verified OA of the study knee of Grade 2 or 3 according to a modification of the\n             grading system of Kellgren-Lawrence (K-L) radiographic severity.\n\n          -  Willingness to discontinue NSAIDs (systemic and topical) and non-acetaminophen\n             analgesic use seven days or five half-lives prior to the first injection and\n             throughout the study.\n\n        Exclusion Criteria:\n\n          -  Inability to perform a 50 foot walk test.\n\n          -  Subjects with rheumatoid arthritis, joint infection, other inflammatory and metabolic\n             arthritis, Lupus or dermatologic disorder or skin conditions in close proximity to\n             study knee that would preclude safe intra-articular injections.\n\n          -  Prior hyaluronic acid injections into the study knee within six months of the\n             screening visit.\n\n          -  Intra-articular or intra-muscular steroid injections within three months of the\n             screening visit or during study participation.  Oral corticosteroids within four\n             weeks of the screening visit or during study participation.\n\n          -  History of surgical treatment to the study knee or arthroscopic intervention within\n             three months prior to the screening visit.\n\n          -  Clinically apparent tense effusion of the study knee on examination determined by\n             either a positive bulge sign or positive ballottement of the patella (patellar tap).\n\n          -  Subjects with clinically diagnosed symptomatic OA of the hip."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "418", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02110238", 
            "org_study_id": "13SUP301"
        }, 
        "intervention": [
            {
                "arm_group_label": "Supartz, 2.5 ml unit dose", 
                "description": "Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2. Subjects will be observed an additional 24 weeks. Participation will be approximately 28 weeks (including the screening period) for the duration of the study.", 
                "intervention_name": "Supartz, 2.5 ml unit dose", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Euflexxa, 2 ml unit dose", 
                "description": "Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2. Subjects will be observed an additional 24 weeks. Participation will be approximately 28 weeks (including the screening period) for the duration of the study.", 
                "intervention_name": "Euflexxa, 2 ml unit dose", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hyaluronic Acid"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "osteoarthritis", 
            "knee pain", 
            "Supartz", 
            "Euflexxa", 
            "HA", 
            "hyaluronic acid"
        ], 
        "lastchanged_date": "April 9, 2014", 
        "location": {
            "contact": {
                "email": "jhallenborg@triangleortho.com", 
                "last_name": "Jan Hallenborg", 
                "phone": "919-281-1698"
            }, 
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27704"
                }, 
                "name": "Triangle Orthopaedic Associates"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicenter, Randomized, Double-Blind, Parallel Controlled Non-Inferiority Clinical Trial Comparing 3 Weekly Intra-articular Injections of SUPARTZ\u00ae vs 3 Weekly Intra-articular Injections of Euflexxa\u00ae for Treatment of Knee OA", 
        "overall_contact": {
            "email": "tawana.wester@bioventusglobal.com", 
            "last_name": "Tawana Wester, RN", 
            "phone": "919-474-6752"
        }, 
        "overall_official": {
            "affiliation": "Stanford University", 
            "last_name": "Vibeke Strand, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To demonstrate non-inferiority of three weekly intra-articular injections of SUPARTZ to three weekly intra-articular injections of Euflexxa for the relief of knee joint pain in subjects with osteoarthritis (OA) of the knee as measured by the VAS (0-100 mm) Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain subscale score Change from Baseline (CFB) over Weeks 3, 6, 12 .", 
            "measure": "Pain Scores on VAS WOMAC", 
            "safety_issue": "No", 
            "time_frame": "Change from Baseline (CFB) over Weeks 3, 6, 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02110238"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bioventus LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "Seikagaku Corporation", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Bioventus LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}